Steven Frank

Presentation
The presentation will consist of the outcomes from the first Phase III multi-center trial of concurrent chemoradiation therapy with IMPT vs IMRT for patients with oropharyngeal cancer.  This randomized trial is 440 patients from 21 sites across the United States.  Results from this trial demonstrate that IMPT is non-inferior to IMRT for progression free survival, improves overall survival, reduces high-grade toxicities, and is a cost-effective new standard of care approach to the management of oropharyngeal cancers.

Bio
Steven J. Frank, MD, is an endowed tenured professor of Radiation Oncology, holds the Bessie McGoldrick Professorship in Clinical Research, and is a fellow of the ABS, ACR, and ASTRO. Dr. Frank is the Executive Director of Technology and Innovation and Deputy Head of Strategy for the Division of Radiation Oncology at the University of Texas MD Anderson Cancer Center. Dr. Frank is amongst the first, if not the first, to use IMPT to treat head and neck tumors, and he is the Principal Investigator of an NIH/NCI/Hitachi-sponsored multi-institutional Phase II/III randomized trial in advanced stage oropharyngeal cancer that compares outcomes after chemoradiation given by IMRT versus IMPT. Dr. Frank has over 350 peer-reviewed publications, has authored many book chapters and has recently published the first textbook on Proton Therapy. Dr. Frank’s lab is studying the biologic enhancement factor of proton therapy and FLASH radiotherapy for both head and neck and prostate cancer. Dr. Frank has served as the chair for the head and neck oral boards and is currently serving on the Radiation Oncology Board of Trustees for the American Board of Radiology.